Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor in dogs. At present, conventional adjuvant chemotherapy provides only a modest survival benefit for treated dogs. Continuous oral administration of low-dose chemotherapy (LDC) has been suggested as an alternative to conventional chemotherapy protocols. Therefore, we… (More)
Fig 3. Disease-free intervals in dogs with hemangiosarcoma treated with adjuvant low-dose continuous chemotherapy (LDC) versus doxorubicin (DOX) chemotherapy. Disease-free intervals were determined and plotted for 9 dogs in the LDC group and 24 dogs in the DOX group. The median disease-free interval of 178 days in LDC group dogs was not significantly different (P 5 .18) from the 126-day median disease-free interval in dogs treated with DOX only.